Clinical trial · Observational
Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy
NCT03724097CI-TRIAL-00053883unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective trial for a computation-based efficacy prediction method for anticancer target therapies. The original computational algorithm utilizes individual transcriptome data of a cancer sample and assesses changes at the level of gene expression and intracellular signaling pathways. By applying the database of known molecular targets of anticancer target drugs it allows to rank potential efficacies of target drugs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| non-target drug | Drug | — | UNRESOLVED |
| palliative care | Drug | — | UNRESOLVED |
| RNA sequencing | Other | — | UNRESOLVED |
| target drug with the score above 0,1 | Drug | — | UNRESOLVED |
| target drug with the score equal or below 0,1 | Drug | — | UNRESOLVED |
| Transcriptome analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1
- description
- Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination
- interventionNames
- Other: RNA sequencing
- Other: Transcriptome analysis
- Drug: target drug with the score above 0,1
- label
- Group 2
- description
- Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination
- interventionNames
- Other: RNA sequencing
- Other: Transcriptome analysis
- Drug: target drug with the score equal or below 0,1
- Drug: non-target drug
- label
- Group 3
- description
- Patients receiving palliative care
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Adults, diagnosed with cancer; * Age 18 - 80; * Patients who previously received anticancer treatment within the standard care, patients for whom standard therapy was not indicated or patients refused to receive standard therapy. Patients could receive an unlimited number of treatment lines before this study; * Available formalin fixed, paraffin-embedded (FFPE) samples of cancer tissue. The material should be confirmed by a certified pathologist, the sample taken for the analysis should contain at least 70% of tumor cells; * Anticipated survival of at least 3 months since the patient's inclusion in the current investigation; * Patients who have signed an informed consent. Exclusion Criteria: * Anticipated survival of less than 3 months since the patient's inclusion in the current investigation; * Lack of tumor biopsy material, inability to obtain a new tumor biopsy.
References
Publications (0)
Data not yet available
No reference posted for this study.